

Acceptance and preference for COVID-19 vaccination in health-care workers (HCWs)

Chuanxi Fu^{δ#}, Zheng wei^{δ#}, Sen Pei[◇], Shunping Li^{ξ§}, Xiaohui Sun^δ, Ping Liu^{ξ§}

From the ^δ Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China 310053

[◇] Mailman School of Public Health, Columbia University, New York, NY 10032, USA

^ξ School of Health Care Management, Shandong University, Jinan, China 250012

[§] NHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China 250012

#Chuanxi Fu and Zheng Wei contributed equally to this work.

Corresponding author: Chuanxi Fu, PhD, Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, No.548, Binwen Rd, Hangzhou, 310053, China.
Tel: +86 537 3605 5887; Fax: +86 537 3743 1722. E-mail: fuchuanxi@gmail.com.

Running head: COVID-19 vaccination in HCWs

Word counts: 2962 (excluded 4 tables, 0 figures and 33 references)

Abstract

The objective of the present study is to reveal the acceptance and preference for the 2019 novel coronavirus disease (COVID-19) vaccination in health-care workers (HCWs). We performed an internet-based, region-stratified survey among 352 HCWs and 189 individuals in the general population enrolled on March 17th and 18th 2020 from 26 Chinese provinces. The HCWs developed a more in-depth understanding of SARS-Coronavirus-2 infection and showed a higher tolerance to the future vaccination than the general population. 76.4% of HCWs (vs. 72.5% in the general) showed their willingness to receive vaccination. Potential benefits from COVID-19 outbreak such as seeking influenza (65.3%) or pneumonia (55.7%) vaccination can be gained in HCWs. To estimate the relative effects of attributes influencing vaccination choice in the discrete choice experiment, 7 attributes (3 disease-relevant, 3 vaccine-relevant, and 1 of social acceptance) were identified as key determinants. Among them, disease trend (odds ratio, OR: 4.367 (95%CI, 3.721-5.126) for seasonal epidemic, OR: 3.069 (2.612-3.605) for persistent epidemic, with reference to disappearance in summer), social contacts' decisions (0.398: 0.339-0.467 for refusal, 0.414: 0.353-0.487 for neutral, with reference to acceptance) and high possibility of being infected (2.076: 1.776-2.425 for infection probability of 30%+) were significantly associated with increased probability of choosing vaccination in the HCWs. In contrast, for the general population, vaccine safety and social contacts' decisions were the most important predictors. For COVID-19 vaccination, education in HCWs should be taken as a priority, and further benefits of its recommendation to the general public will also be anticipated.

Keywords: COVID-19, Health-care workers (HCWs), Acceptance, Discrete choice experiment (DCE), Preference

Introduction

Originated from Wuhan in Central China in December 2019 and widely spread due to the highly contagious pathogen SARS-Coronavirus-2 (SARS-CoV-2) in a completely susceptible population, the 2019 novel coronavirus disease (COVID-19) has soon evolved to a global pandemic sweeping across over 144 countries, leading to 153 thousands cases and 5735 deaths, by 15th March 2020, accompanying with potentially substantial economic loss(1-3). The unspecified interventions such as social distancing and quarantine can slow down the spread of virus and flatten the epidemic curve(4); however, the COVID-19 epidemic will not stop unless herd immunity is well established within the population, which is usually gained by infection or vaccination. Although at least 40 pharmaceutical companies and academic institutions have launched their programs on vaccine development against SARS-CoV-2 infection and some of them have reached early phase clinical trials(5), the safety and vaccine efficacy should be fully understood before it can be used in the real world.

Hesitancy usually arises when a vaccine is introduced to the public about its effectiveness and potential safety. Complacency of not getting infected, lack of confidence in the safety & effectiveness of vaccine and vaccination service system, convenience of seeking service and higher expense than expected could eventually reduce the possibility of accepting the vaccination(6, 7). Besides under a higher risk of getting infected by various pathogens such as influenza viruses and SARS-CoV-2 than the general population(8, 9), health-care workers (HCWs) are also vital in helping the vaccinees or guardians understand and accept the vaccination. The importance of HCWs' vaccination recommendation to the public in the decision-making process has been well documented and HCWs are one of the strongest influencers in vaccination decisions(10-12).

Discrete choice experiment (DCE) presents a series of choice sets. How people make trade-offs among different attributes and levels indicates the relative importance of these attributes in decision preference(13). However, there have been limited studies using DCE to explore the preferences for vaccination(14-16). In this study, we sought to report the expectation and acceptance of future COVID-19 vaccine in HCWs compared with the general population, and to further reveal the preferences for COVID-19 vaccination.

Materials and methods

Subjects and design

Study subjects are HCWs of 20-59 years old from hospitals, center for disease control and prevention (CDC) or health community centers. According to the total number of reported confirmed COVID-19 cases till 15th Mar, 2020(17), we divided all provinces in mainland China into two categories: (i) high-level epidemic areas with 1000+ cases including Hubei, Guangdong, Zhejiang and Henan, (ii) low-level epidemic areas with < 1000 cases.

On March 17th and 18th 2020, we initiated an online survey by snowball sampling via WeChat invitation. We firstly invited 20 individuals via a link to the survey, with 10 from area (i) and 10 from area (ii). Each of the enrolees was then asked to invite 20-30 subjects of their social contacts to fill out the online questionnaire. To compare how COVID-19 vaccination acceptance differed in HCWs from the general population, adult subjects without medical backgrounds were also invited in the study, enrolling about half of the number of HCWs subjects.

Data collection

The survey was carried out using a self-administered, anonymous questionnaire, which consisted of 5 sections: (i) Demographics information; (ii) seven items for knowledge of and attitude to SARS-CoV-2 infection including susceptible individuals, various health outcomes, sub-population who tend to die after being infected, effective treatment, virus mutation, epidemic trend (disappear in summer like SARS, seasonal epidemic like seasonal influenza, persistent chronic disease like tuberculosis), and possibility of getting infected; (iii) ten items for the acceptability of COVID-19 vaccination including the necessity, months to availability on the market, the most needed to be vaccinated, desire to receive the vaccination, the lowest effectiveness, the most serious adverse effects, the highest number of doses, and the highest expense that could be accepted, and the confidence in domestic manufactured vaccines; (iv) behaviours post epidemic including plans to receive seasonal influenza vaccine or pneumococcal vaccine and maintaining of other unspecified protective measures; (v) Preferences for vaccination decision. All the questions were based on evidence in existing literature. The SO JUMP, an online survey platform, was employed to conduct the online investigation (see Supplemental material 1 and 2).

Discrete choice experiment

Seven attributes were finally identified as the key determinants of vaccination decisions based on group discussion and pilot investigation: three disease-relevant attributes (probability of infection, severity and probability of death once infected, and trend of epidemic), three vaccine-relevant attributes (vaccine effectiveness, vaccine safety and out-of-pocket vaccination cost), and one attribute of social acceptance (Table 1). A fractional factorial design based on orthogonal arrays (ORTHOPLAN procedure, IBM SPSS Statistics) was used to select 16 hypothetical profiles derived from 648 ($3 \times 2 \times 3 \times 2 \times 2 \times 3 \times 3$) candidate attribute profiles. Then the selected profiles were randomly distributed to 8 choice sets, each comprised of two hypothetical profiles (Scenario A and Scenario B). For each choice set, all participants were invited to make their COVID-19 vaccination decisions from either scenario A or B. An extra choice set was established to identify subjects being potentially ‘irrational’ or unable to understand the choices, in which scenario A instead of B would be logically chosen for sensitive analysis.

Data statistics

In the equation below, β_1 -11 are random coefficients varied over individuals; X_i is a vector of alternative specific variables; β_0 is a constant term, and Error is a random term following a type I extreme value distribution. A binary Logistic regression was employed to assess the preference weight (odds ratio, OR) for each attribute level in determining whether to get vaccinated or not.

$$C_{\text{vaccinated or not}} = \text{Error} + \beta_0 + X_1\beta_1_{\text{Infection probability (1.5-3.0\%/1-1.4\%)}} + X_2\beta_2_{\text{Infection probability (>3.0\%/1-1.4\%)}} + X_3\beta_3_{\text{Case-fatality ratio (3\%-1.5\%/<3\%)}} \\ + X_4\beta_4_{\text{Trend of epidemic (flu/sars)}} + X_5\beta_5_{\text{Trend of epidemic (pb/sars)}} + X_6\beta_6_{\text{Vaccine safety (safe/uncertain)}} + X_7\beta_7_{\text{Vaccine effectiveness (\ge 80\%/50\%-80\%)}} \\ + X_8\beta_8_{\text{cost (100/free)}} + X_9\beta_9_{\text{cost (300/free)}} + \beta_{10}_{\text{Acceptance of social contacts (Encourage/ Neutral/no opinion)}} + \beta_{11}_{\text{Acceptance of social contacts (Refuse/ Neutral/no opinion)}}$$

Descriptive analysis was performed using SPSS Version 25.0 (IBM Corporation, New York, United States) and statistics DCE process was carried out in STATA 16. The study approval was obtained from the Institutional Review Board of Zhejiang Chinese Medical University (ZCMU) and anonymity was guaranteed to participants.

Results

Demographic characteristics

In total 561 of 583 subjects who were approached completed the online survey, yielding a response rate of 96.2%. Of the 561 eligible participants, 20 (3.56%) were excluded from the analysis (13 living outside of China, 7 out of age limit). We included 541 participants from 26 provinces in China in the analysis.

Approximately 303 (56%) of the respondents were from area (i) (Hubei, Guangdong, and Zhejiang), with 70 (23%) from Wuhan. The characteristics of gender and age were comparable between the HCWs (n=352, 65%) and individuals from the general population. Nearly 60% of the HCWs were females and 90% were well educated with a degree of bachelor or above (Table 2).

Knowledge on and attitude to COVID-19

Overall the HCWs developed a more in-depth understanding of the infection and disease than the general population. The majority of HCWs recognized that all age groups are susceptible to the novel virus (305, 86.6%), and there is an increased risk of death in infected individuals of the elderly or with chronic diseases (349, 99.1%). Nearly 90% of the HCWs believed that there have been slight mutations and 7% believed dramatic mutations of the virus. Of the 141 HCWs who reported their views for COVID-19 trend, 47.5% (n=67) believed it would diminish in summer, 44.7% (n=63) believed it would continue to spread periodically, and only 8% (n=11) believed that it would evolve to a chronic disease.

Regarding the risk of COVID-19, 66% of the HCWs thought they might be infected in future, which is higher than that in the general population (52%).

Expectation and acceptance of COVID-19 vaccination

As to the COVID-19 vaccine under development, 95% of the HCWs thought it is necessary. The HCWs showed a higher tolerance to the future vaccine. Compared with general population, the HCWs believed that more time is needed before the vaccine could be introduced into use, could accept lower least-protection, more severe adverse effects such as systematic reaction and allergic reactions, and more minor-lesions or severe lesions than general population (Table 2).

About half of HCWs (52.5%) believed that the COVID-19 vaccine by domestic manufactures would be better than those produced abroad, which is lower than the general population (65.6%). For the possible reasons that domestic vaccine could be inferior, about 60% HCWs

chose the poor quality due to less strictly controlled production process, and 60% general individuals chose vaccine safety that could not be fully guaranteed. For all subjects, 80% agreed that it should be free of charge and nearly half could afford a cost of 100-299 RMB (14-42 dollars) for total doses. Three quarters of the HCWs would receive vaccination against COVID-19; however, nearly one fifth needed more information before they could finally make their decisions.

Protection adopted post epidemic

When the epidemic ends, about 70% HCWs would seek and receive vaccination against influenza or pneumonia. The HCWs would prefer influenza vaccination (65.3%) while the general population prefers the pneumococcal vaccination (58.7%). The subjects would reduce the frequency of going to the crowded (74%), keep washing hands frequently (96%), doing exercises (93%), and wearing mask (67%) in the future.

Vaccine preference actors

Seasonal epidemic (OR: 4.4) or persistence (OR: 3.1), social contacts' vaccination practice (OR: 2.4 and 2.5), high possibility of infection (>30%) (OR: 2.1), fee (OR: 2.1 and 1.7), vaccine effectiveness (OR: 1.8) and safety (OR: 1.5) have much stronger effects on the COVID-19 vaccination decisions than the infection possibility of 15%-30% (1.0) or severity (OR: 0.99) in the HCWs (Table 3). This indicates that disease trend in the future and high possibility of being infected may increase the importance of disease-relevant attributes relative to vaccine-attributes in the decision-making of HCWs.

Similar or weaker effects of attributes on vaccination preference were found in the general population. However, general population seems to focus more on vaccine safety (OR: 2.3), social contacts' decisions (OR: 4.7 and 2.1) and case-fatality ratio (OR: 1.3) than HCWs.

Sensitive analysis based on 445 subjects shown in Table 4 indicates that similar effects were found for all choice sets for HCWs and the general population.

Discussion

Using an internet-based, region-stratified study from 26 provinces in China, we surveyed population's knowledge on COVID-19 and their attitude towards future vaccination in China. Compared with the general population, HCWs showed more tolerance on the adverse effects and the effectiveness of vaccine. Further potential benefits from the epidemic such as influenza or pneumonia vaccination can be gained from the epidemic. Disease trend, social contacts' decisions and high possibility of being infected are significantly associated with increased probability of choosing vaccination among HCWs, while for the general population, vaccine safety and social contacts' decisions are the most important predictors. Most HCWs (3/4) showed their willingness to receive the COVID-19 vaccination after introduction, which, to a large extent, is due to the risk evaluation of infection and confidence in the effectiveness and safety of vaccine. HCWs had a much higher possibility of getting infected by the novel virus. For example, by Feb 11th, 2020, with 6 deaths, 1716 HCWs were reported to get COVID-19 in China(18). In our study, 66% of the HCWs believe they may be infected by the virus from close contacts with COVID-19 cases or daily contacts. The uncertainty in how the epidemic will develop also contributes to the risk evaluation - 60% HCWs in the study don't know the possible trend.

HCWs showed a positive attitude towards the vaccine. They can accept a lower effectiveness of 60-70% (just as seasonal influenza vaccine), more severe adverse effects, and a larger number of doses. HCWs are vital to the public's decisions to receive the vaccination, which can eventually increase vaccine coverage. Knowledge and acceptance were found to increase a HCW's willingness to recommended vaccination. One study in the UK reported that nurses with high knowledge scores were more likely to recommend influenza vaccine to their parents, and more willing to recommend vaccination to parents in the future(19). In a study on HPV vaccination in Cameroon, one of the most important factors considered amongst nurses when deciding to recommend vaccine is the understanding of the effectiveness and safety of the vaccine(20).

The percentage of HCWs willing to get vaccinated in our study during the epidemic of COVID-19 is much higher than that for the general population as well as previous results in a systematic review during the 2009 H1N1 pandemic (56.1% in the UK, 64% in the US and 54.7% in Australia)(21-23). Regarding the H7N9 vaccination, 59.5% of the general population in Beijing and 50.5% of the respondents in Hongkong China were reported to have the

willingness to receive the vaccination(24, 25). However, most estimates of vaccination intention tend to be much greater than actual vaccine coverage estimates. In our study, nearly 20% of the HCWs and 25% of the general population are hesitant about COVID-19 vaccination, which may be a hinder to establish herd immunity within the population. A lack of preparedness for advising patients about vaccination and a lack of training are inhibiting factors for recommending the vaccine. For example, in a UK study with midwives, 76% agreed that they should routinely advise pregnant women on vaccination, but only 25% felt adequately prepared for the role(26). More efforts need to be made to increase the acceptance of vaccination in HCWs and the public.

Worried about poor vaccine quality produced by domestic manufacturers, certain HCWs may develop vaccine hesitancy, which could influence their own decisions and the vaccination recommendation to the public. In the study, the proportion of HCWs thinking ‘domestic vaccine was inferior’ is twice as in the public (7% vs. 3%). Basically, different from HCWs from western countries who are hesitant to the vaccine itself, 60% Chinese HCWs focus on the less strict quality control during the production instead of vaccines. Incidences of vaccines such as Changchun Changsheng Biotech reported in China in the past decade may lead to the decline of confidence in domestic vaccines among the Chinese including HCWs(27, 28). Similar to human body’s immune memory and reactivation in the way vaccine works, HCWs or the public will show much more grief and indignation towards the future COVID-19 vaccine if serious adverse events are reported after vaccine introduction. Under the newly introduced Vaccine Management Law came into effect in late 2019, the country will find a chance to improve domestic vaccines including vaccine research, production and mass vaccination campaigns.

Further potential benefits from COVID-19 epidemic can be gained, in that the epidemic is a sound health education against infectious diseases. Health protection including receiving more vaccinations as well as wearing mask were observed in our study. Different levels of knowledge and risk evaluation on SARS-CoV-2 infection might explain the difference between HCWs and the public in choosing vaccinations. Increased perception to influenza burden, indicated by insufficient supply of vaccine in recent years(29, 30), and the assumption that the COVID-19 was an ‘enhanced influenza’ may contribute to the increased willingness to influenza vaccination in HCWs. The public begin to reach out for the

pneumonia vaccine, partially in that they are scared with the COVID-19 that may seriously attack human's lungs(31).

Seasonal or persistent trend for COVID-19 epidemic is far more influential on vaccination choice than the infection probability or case-fatality ratio. This suggests that HCWs value much more the future trend than risk probability or consequences. The choice might be motivated by seasonal influenza vaccination, for which the virus circulates with seasonality annually. Different from HCWs, the general population in the study showed more attention to the COVID-19 vaccine safety. It is natural that the public usually completely or partially refuses the vaccination when an emerging vaccine is in use. Due to a lack of knowledge of vaccine, they have to make trade-offs between the adverse outcomes of vaccination and the disease burden, indicating education should be strengthened at this stage.

Social contacts, including the behaviors and attitude of relatives, friends and neighbors, play an importance role in decision for both HCWs and the general population. Uncertainty in the vaccination choice or being socially acceptable may contribute to the cautious or wait-and-see attitude. When vaccine safety or effectiveness is uncertain, external cues such as others' vaccination uptake will greatly help to strength or weaken the vaccination intent(16). On the other hand, individuals, especially in eastern countries, usually have a virtue of lack their own subjective judgments because of the cultural or traditional circumstances(32). The collectivism culture, which is vital in executing the social distancing activities during the first wave of COVID-19 epidemic in China, may hinder the vaccination when the COVID-19 vaccination is firstly launched.

Disease severity is not related to the vaccination decision in HCWs and exhibits a weak reversed association in the general sample (the upper CI for OR almost reaching 1.0). This is in accordance with what has been reported in other vaccine preventable diseases such as influenza(16). The emerging infectious disease of COVID-19, for its unknown origin, clinical therapy and possible transmissions, may weaken the vaccination decision in the study, which should be examined in future study.

There are several limitations in the present study. First, subjects were recruited and surveyed online instead of face-to-face interview, which may lead to potential bias for the DCE study. Second, we do not distinguish doctors and nurses in hospitals, health providers in the community or those in the center for disease control and preventions, who may have different levels of knowledge and choice decision.

Factors contributed to a vaccination decision include personal risk perception, vaccination attitude or motivation, information sources, access and demographic variables, as well as social influences and practical factors(33). For the future COVID-19 vaccination, an efficient and flexible vaccination system nationwide to ensure fair and affordable services is necessary. In this system, vaccine demand and hesitancy in various populations should be addressed. Multi-component interventions should be taken into consideration. Education in HCWs should be taken as a priority so that further benefit of their recommendation to the public could be anticipated.

Acknowledgements

This work was not supported by any grant.

Declaration of interest statement

No potential conflict of interest was reported by the authors.

Supplemental online materials

Supplemental 1: The online questionnaire of COVID-19 vaccination acceptance and preference (in English)

Supplemental 2: The online questionnaire of COVID-19 vaccination acceptance and preference (in Chinese)

Tables & Figures

Table 1 Attributes and levels included in the discrete choice experiment

| Attributes | Levels |
|----------------------------------|-----------------------------------|
| Infection probability | 1%-14% |
| | 15%-30% |
| | >30% |
| Case-fatality ratio | <3% |
| | 3%-15% |
| Trend of epidemic | Disappear in summer, like SARS |
| | Seasonal epidemic, like influenza |
| | Nonchronic, like tuberculosis |
| Vaccine safety | Safe with mild side effects |
| | Uncertain, it is a new vaccine |
| Vaccine effectiveness | 50%-80% |
| | >80% |
| Out of pocket of the vaccination | Free |
| | RMB 100 (US \$14.3) |
| | RMB 300 (US \$42.9) |
| Acceptance of social contacts | Refuse |
| | Neutral/no opinion |
| | Encourage |

Table 2 Characteristics of the study subjects and acceptance of COVID-19 vaccine

| | | Total | HCWs | General | X ² | p |
|----------------------------|--------------------------------------|-----------|-----------|-----------|----------------|--------|
| Area | Area (i) | 303(56.0) | 170(48.3) | 133(70.4) | 24.321 | <0.001 |
| | Area (ii) | 238(44.0) | 182(51.7) | 56(29.6) | | |
| Gender | Male | 230(42.5) | 145(41.2) | 85(45.0) | 0.719 | 0.396 |
| | Female | 311(57.5) | 207(58.8) | 104(55.0) | | |
| Education | Maser or above | 149(27.5) | 114(32.4) | 35(18.5) | 65.057 | <0.001 |
| | Bachelor | 276(51.0) | 199(56.5) | 77(40.7) | | |
| | Low than bachelor | 116(21.4) | 39(11.1) | 77(40.7) | | |
| Age group | 20-29 | 212(39.2) | 130(36.9) | 82(43.4) | 4.834 | 0.184 |
| | 30-39 | 175(32.3) | 112(31.8) | 63(33.3) | | |
| | 40-49 | 106(19.6) | 78(22.2) | 28(14.8) | | |
| | 50-59 | 48(8.9) | 32(9.1) | 16(8.5) | | |
| Vulnerable | All | 463(85.6) | 305(86.6) | 158(83.6) | 0.927 | 0.336 |
| | Subgroup | 78(14.4) | 47(13.4) | 31(16.4) | | |
| Easily die after infection | The elderly or with chronic diseases | 537(99.3) | 349(99.1) | 188(99.5) | 0.175 | 0.676 |
| | Other | 4(0.7) | 3(0.9) | 1(0.5) | | |
| Effective drug | No | 478(88.4) | 325(92.3) | 153(81.0) | 28.789 | <0.001 |
| | Yes | 20(3.7) | 15(4.3) | 5(2.6) | | |
| | No know | 43(7.9) | 12(3.4) | 31(16.4) | | |
| Virus variation | No | 32(5.9) | 14(4.0) | 18(9.5) | 20.861 | <0.001 |
| | Slight | 454(83.9) | 314(89.2) | 140(74.1) | | |
| | Dramatic | 55(10.2) | 24(6.8) | 31(16.4) | | |
| Trend of COVID-19 | Diminish | 98(18.1) | 67(19.0) | 31(16.4) | 13.219 | 0.004 |
| | Seasonal epidemic | 79(14.6) | 63(17.9) | 16(8.5) | | |
| | Constant epidemic | 24(4.4) | 11(3.1) | 13(6.9) | | |
| | No sure | 340(62.8) | 211(59.9) | 129(68.3) | | |
| Be infected in future | No | 210(38.8) | 119(33.8) | 91(48.1) | 10.65 | 0.001 |
| | Possible | 331(61.2) | 233(66.2) | 98(51.9) | | |
| Necessary to vaccine | Yes | 517(95.6) | 335(95.2) | 182(96.3) | 1.001 | 0.606 |
| | No | 10(1.8) | 8(2.3) | 2(1.1) | | |
| | Not sure | 14(2.6) | 9(2.6) | 5(2.6) | | |
| Time before in use | in 6 months | 162(29.9) | 96(27.3) | 66(34.9) | 8.612 | 0.035 |
| | In 1 year | 219(40.5) | 144(40.9) | 75(39.7) | | |
| | in 1.5 year | 69(12.8) | 42(11.9) | 27(14.3) | | |
| | More | 91(16.8) | 70(19.9) | 21(11.1) | | |
| Receiving COVID-19 vaccine | No | 20(3.7) | 15(4.3) | 5(2.6) | 2.904 | 0.234 |
| | Yes | 406(75.0) | 269(76.4) | 137(72.5) | | |
| | Not sure | 115(21.3) | 68(19.3) | 47(24.9) | | |
| Most doses | 1 | 39(7.2) | 28(8.0) | 11(5.8) | 9.582 | 0.048 |
| | 2 | 155(28.7) | 109(31.0) | 46(24.3) | | |
| | 3 | 138(25.5) | 95(27.0) | 43(22.8) | | |

| | | | | | | |
|------------------------------|--------------------|-----------|-----------|-----------|--------|-------|
| | 4 | 7(1.3) | 3(0.9) | 4(2.1) | | |
| | Not sure | 202(37.3) | 117(33.2) | 85(45.0) | | |
| Least vaccine effectiveness | <60% | 16(3.0) | 8(2.3) | 8(4.2) | 12.178 | 0.007 |
| | 60-69% | 247(45.7) | 178(50.6) | 69(36.5) | | |
| | 70-89% | 152(28.1) | 96(27.3) | 56(29.6) | | |
| | ≥90% | 126(23.3) | 70(19.9) | 56(29.6) | | |
| Local reaction | No | 20(3.7) | 10(2.8) | 10(5.3) | 2.073 | 0.15 |
| | Yes | 521(96.3) | 342(97.2) | 179(94.7) | | |
| Systematic reaction | No | 227(42.0) | 133(37.8) | 94(49.7) | 7.212 | 0.007 |
| | Yes | 314(58.0) | 219(62.2) | 95(50.3) | | |
| Allergic reactions | No | 342(63.2) | 215(61.1) | 127(67.2) | 1.978 | 0.16 |
| | Yes | 199(36.8) | 137(38.9) | 62(32.8) | | |
| Minor lesions | No | 505(93.3) | 321(91.2) | 184(97.4) | 7.515 | 0.006 |
| | Yes | 36(6.7) | 31(8.8) | 5(2.6) | | |
| Severe lesions | No | 530(98.0) | 344(97.7) | 186(98.4) | 0.29 | 0.59 |
| | Yes | 11(2.0) | 8(2.3) | 3(1.6) | | |
| Confidence domestic vaccines | Better than aboard | 273(50.5) | 168(47.7) | 105(55.6) | 13.016 | 0.005 |
| | Similar | 180(33.3) | 130(36.9) | 50(26.5) | | |
| | Worse | 27(5.0) | 22(6.3) | 5(2.6) | | |
| | not sure | 61(11.3) | 32(9.1) | 29(15.3) | | |
| Worse | Low VE | 5(18.5) | 5(22.7) | 0(0) | 4.512 | 0.125 |
| | Safety | 7(25.9) | 4(18.2) | 3(60.0) | | |
| | Quality | 15(55.6) | 13(59.1) | 2(40.0) | | |
| Free of charge | Yes | 432(79.9) | 276(78.4) | 156(82.5) | 1.304 | 0.253 |
| | No | 109(20.1) | 76(21.6) | 33(17.5) | | |
| Highest fee | <100 | 167(30.9) | 108(30.7) | 59(31.2) | 0.897 | 0.826 |
| | 100-299 | 281(51.9) | 184(52.3) | 97(51.3) | | |
| | 300-499 | 62(11.5) | 42(11.9) | 20(10.6) | | |
| | ≥500 | 31(5.7) | 18(5.1) | 13(6.9) | | |
| Vaccination post epidemic | Influenza | 69(12.8) | 56(15.9) | 13(6.9) | 16.593 | 0.001 |
| | Pneumonia | 47(8.7) | 22(6.3) | 25(13.2) | | |
| | Both | 260(48.1) | 174(49.4) | 86(45.5) | | |
| | None | 165(30.1) | 100(28.4) | 65(34.4) | | |
| Less to crowded | No | 139(25.7) | 86(24.4) | 53(28.0) | 0.84 | 0.359 |
| | Yes | 402(74.3) | 266(75.6) | 136(72.0) | | |
| Wash hands frequently | No | 23(4.3) | 12(3.4) | 11(5.8) | 1.756 | 0.185 |
| | Yes | 518(95.7) | 340(96.6) | 178(94.2) | | |
| Wear mask | No | 177(32.7) | 118(33.5) | 59(31.2) | 0.297 | 0.586 |
| | Yes | 364(67.3) | 234(66.5) | 130(68.8) | | |
| Exercises | No | 40(7.4) | 26(7.4) | 14(7.4) | 0 | 0.993 |
| | Yes | 501(92.6) | 326(92.6) | 175(92.6) | | |

Table 3 Preference for COVID vaccination for HCWs and the general population(n=445)

| Variables | HCWs (N=302) | | | General Population (N=143) | | |
|---|--------------------|-------|-------|------------------------------|-------|-------|
| | OR (95%CI) | SE | p | OR (95%CI) | SE | p |
| Infection probability | | | | | | |
| 1%-14% | 1.000 | | | 1.000 | | |
| 15%-30% | 1.007(0.855-1.186) | 0.084 | 0.933 | 1.012(0.808-1.268) | 0.116 | 0.919 |
| >30% | 2.076(1.776-2.425) | 0.163 | *** | 2.007(1.600-2.517) | 0.232 | *** |
| Case-fatality ratio | | | | | | |
| <3% | 1.000 | | | 1.000 | | |
| 3%-15% | 0.992(0.872-1.127) | 0.065 | 0.899 | 0.783(0.649-0.943) | 0.746 | * |
| Trend of epidemic | | | | | | |
| Dimish in summer, like SARS | 1.000 | | | 1.000 | | |
| Seasonal epidemic, like influenza | 4.367(3.721-5.126) | 0.357 | *** | 2.149(1.721-2.683) | 0.243 | *** |
| Nonchronic, like TB | 3.069(2.612-3.605) | 0.252 | *** | 1.609(1.261-2.054) | 0.200 | *** |
| Vaccine safety | | | | | | |
| Uncertain, it is a new vaccine | 1.000 | | | 1.000 | | |
| Safe with mild side effects | 1.541(1.354-1.754) | 0.102 | *** | 2.288(1.897-2.760) | 0.219 | *** |
| Vaccine effectiveness | | | | | | |
| 50%-80% | 1.000 | | | 1.000 | | |
| >80% | 1.770(1.536-2.039) | 0.128 | *** | 1.788(1.461-2.189) | 0.185 | *** |
| Out of pocket of the vaccination | | | | | | |
| Free | 1.000 | | | 1.000 | | |
| RMB 100 (US \$14.3) | 0.576(0.496-0.669) | 0.044 | *** | 0.787(0.632-0.979) | 0.088 | * |
| RMB 300 (US \$42.9) | 0.476(0.403-0.561) | 0.040 | *** | 0.584(0.459-0.744) | 0.072 | *** |
| Acceptance of social contacts | | | | | | |
| Encourage | 1.000 | | | 1.000 | | |
| Neutral/no opinion | 0.414(0.353-0.487) | 0.034 | *** | 0.484(0.389-0.602) | 0.054 | *** |
| Refuse | 0.398(0.339-0.467) | 0.033 | *** | 0.212(0.165-0.273) | 0.027 | *** |
| Log likelihood | -2839.4509 | | | -1354.136 | | |
| Number of obs | 4832 | | | 2288 | | |
| Prob > chi2 | *** | | | *** | | |
| Pseudo R2 | 0.1522 | | | 0.1462 | | |

Note, OR: Odds ratio, SE: standardized error.

* p<0.05 for statistical significance.

** p<0.01 for statistical significance.

*** p<0.001 for statistical significance.

Table 4 Preferences based on 9 choice sets (n=541)

| Variables | HCWs (N=352) | | | General Population (N=189) | | |
|---|--------------------|-------|-------|------------------------------|-------|-------|
| | OR (95%CI) | SE | p | OR (95%CI) | SE | p |
| Infection probability | | | | | | |
| 1%-14% | 1.000 | | | 1.000 | | |
| 15%-30% | 0.924(0.798-1.069) | 0.069 | 0.286 | 0.859(0.714-1.034) | 0.081 | 0.109 |
| >30% | 1.781(1.555-2.040) | 0.123 | *** | 1.373(1.149-1.642) | 0.125 | *** |
| Case-fatality ratio | | | | | | |
| <3% | 1.000 | | | 1.000 | | |
| 3%-15% | 1.016(0.907-1.138) | 0.059 | 0.782 | 0.825(0.710-0.959) | 0.063 | * |
| Trend of epidemic | | | | | | |
| Dimish in summer, like SARS | 1.000 | | | 1.000 | | |
| Seasonal epidemic, like influenza | 3.436(2.996-3.942) | 0.240 | *** | 1.660(1.389-1.985) | 0.151 | *** |
| Nonchronic, like TB | 2.702(2.338-3.122) | 0.199 | *** | 1.422(1.170-1.729) | 0.142 | *** |
| Vaccine safety | | | | | | |
| Uncertain, it is a new vaccine | 1.000 | | | 1.000 | | |
| Safe with mild side effects | 1.602(1.429-1.796) | 0.093 | *** | 2.033(1.751-2.360) | 0.155 | *** |
| Vaccine effectiveness | | | | | | |
| 50%-80% | 1.000 | | | 1.000 | | |
| >80% | 1.643(1.446-1.867) | 0.107 | *** | 1.593(1.344-1.887) | 0.138 | *** |
| Out of pocket of the vaccination | | | | | | |
| Free | 1.000 | | | 1.000 | | |
| RMB 100 (US \$14.3) | 0.561(0.491-0.641) | 0.038 | *** | 0.670(0.561-0.800) | 0.061 | *** |
| RMB 300 (US \$42.9) | 0.481(0.416-0.555) | 0.035 | *** | 0.619(0.513-0.748) | 0.060 | *** |
| Acceptance of social contacts | | | | | | |
| Encourage | 1.000 | | | 1.000 | | |
| Neutral/no opinion | 0.437(0.378-0.504) | 0.032 | *** | 0.509(0.424-0.612) | 0.048 | *** |
| Refuse | 0.448(0.390-0.515) | 0.032 | *** | 0.335(0.278-0.404) | 0.032 | *** |
| Log likelihood | -3683.9401 | | | -2076.8354 | | |
| Number of obs | 6336 | | | 3402 | | |
| Prob > chi2 | *** | | | *** | | |
| Pseudo R ² | 0.1612 | | | 0.1193 | | |

Note, OR: Odds ratio, SE: standardized error.

* p<0.05 for statistical significance.

** p<0.01 for statistical significance.

*** p<0.001 for statistical significance.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020 Mar 26;382(13):1199-207.
2. World Health Organization. Situation report - 55. Coronavirus disease 2019 (COVID-19) [cited 2020 Mar 15]; Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200315-sitrep-55-covid-19.pdf?sfvrsn=33daa5cb_8
3. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*. 2020 Mar 16.
4. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? *Lancet*. 2020 Mar 21;395(10228):931-4.
5. Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. *Vaccines (Basel)*. 2020 Mar 29;8(2).
6. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring trust in vaccination: A systematic review. *Hum Vaccin Immunother*. 2018 Jul 3;14(7):1599-609.
7. MacDonald NE, Hesitancy SWGoV. Vaccine hesitancy: Definition, scope and determinants. *Vaccine*. 2015 Aug 14;33(34):4161-4.
8. The L. COVID-19: protecting health-care workers. *Lancet*. 2020 Mar 21;395(10228):922.
9. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. *Lancet*. 2000 Jan 8;355(9198):93-7.
10. Dempsey AF, Pyrznowski J, Lockhart S, Barnard J, Campagna EJ, Garrett K, et al. Effect of a Health Care Professional Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized Clinical Trial. *JAMA Pediatr*. 2018 May 7;172(5):e180016.
11. Kempe A, O'Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, et al. HPV Vaccine Delivery Practices by Primary Care Physicians. *Pediatrics*. 2019 Oct;144(4).
12. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine hesitancy and healthcare providers. *Vaccine*. 2016 Dec 20;34(52):6700-6.
13. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. *Health Econ*. 2012 Feb;21(2):145-72.
14. Brown DS, Poulos C, Johnson FR, Chamiec-Case L, Messonnier ML. Adolescent girls' preferences for HPV vaccines: a discrete choice experiment. *Adv Health Econ Health Serv Res*. 2014;24:93-121.
15. Eilers R, de Melker HE, Veldwijk J, Krabbe PFM. Vaccine preferences and acceptance of older adults. *Vaccine*. 2017 May 15;35(21):2823-30.
16. Liao Q, Lam WWT, Wong CKH, Lam C, Chen J, Fielding R. The relative effects of determinants on Chinese adults' decision for influenza vaccination choice: What is the effect of priming? *Vaccine*. 2019 Jul 9;37(30):4124-32.
17. China NHCotPsRo. Update on COVID-19 as of 24:00 on Mar 15. [cited; Available from: <http://www.nhc.gov.cn/xcs/yqtb/202003/114113d25c1d47aabe68381e836f06a8.shtml>]

18. China NHCotPsRo. State Council press conference on Feb 14 2020. [cited; Available from: <http://www.nhc.gov.cn/xwzb/webcontroller.do?titleSeq=11231&gecstype=1>
19. Zhang J, While AE, Norman IJ. Nurses' vaccination against pandemic H1N1 influenza and their knowledge and other factors. *Vaccine*. 2012 Jul 6;30(32):4813-9.
20. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Welty T, et al. Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: an exploratory study. *Int J Nurs Stud*. 2013 Oct;50(10):1399-406.
21. Nguyen T, Henningsen KH, Brehaut JC, Hoe E, Wilson K. Acceptance of a pandemic influenza vaccine: a systematic review of surveys of the general public. *Infect Drug Resist*. 2011;4:197-207.
22. Rubin GJ, Potts HW, Michie S. The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK. *Health Technol Assess*. 2010 Jul;14(34):183-266.
23. Horney JA, Moore Z, Davis M, MacDonald PD. Intent to receive pandemic influenza A (H1N1) vaccine, compliance with social distancing and sources of information in NC, 2009. *PLoS One*. 2010 Jun 18;5(6):e11226.
24. Chan EY, Cheng CK, Tam GC, Huang Z, Lee PY. Willingness of future A/H7N9 influenza vaccine uptake: A cross-sectional study of Hong Kong community. *Vaccine*. 2015 Sep 11;33(38):4737-40.
25. Wu S, Su J, Yang P, Zhang H, Li H, Chu Y, et al. Willingness to accept a future influenza A(H7N9) vaccine in Beijing, China. *Vaccine*. 2018 Jan 25;36(4):491-7.
26. Ishola DA, Jr., Permalloo N, Cordery RJ, Anderson SR. Midwives' influenza vaccine uptake and their views on vaccination of pregnant women. *J Public Health (Oxf)*. 2013 Dec;35(4):570-7.
27. Fu C. Milestone and challenges: lessons from defective vaccine incidents in China. *Hum Vaccin Immunother*. 2020;16(1):80.
28. Yu W, Liu D, Zheng J, Liu Y, An Z, Rodewald L, et al. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China. *Int J Epidemiol*. 2016 Apr;45(2):441-9.
29. Li L, Liu Y, Wu P, Peng Z, Wang X, Chen T, et al. Influenza-associated excess respiratory mortality in China, 2010-15: a population-based study. *Lancet Public Health*. 2019 Sep;4(9):e473-e81.
30. Ren X, Geoffroy E, Tian K, Wang L, Feng L, Feng J, et al. Knowledge, Attitudes, and Behaviors (KAB) of Influenza Vaccination in China: A Cross-Sectional Study in 2017/2018. *Vaccines (Basel)*. 2019 Dec 26;8(1).
31. Zhan S, Yang YY, Fu C. Public's early response to the novel coronavirus-infected pneumonia. *Emerg Microbes Infect*. 2020;9(1):534.
32. Yang Y. *Health research: social and behavioral theory and methods*. 2nd ed. Beijing: People Medical Publishing House; 2017.
33. WHO. Improving vaccination demand and addressing hesitancy. 2019 16 August 2019 [cited 2019 16 August]; Available from: https://www.who.int/immunization/programmes_systems/vaccine_hesitancy/en/